The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant mammalian target of rapamycin (mTOR) activation drives non-small-cell lung carcinoma (NSCLC) tumorigenesis and progression.
• mTOR kinase inhibitors represent a therapeutic strategy for NSCLC.

Purpose of the Study:

• To evaluate the anti-NSCLC potential of PQR620, a novel mTOR kinase inhibitor.
• To elucidate the mechanisms underlying PQR620's activity in NSCLC cells.

Main Methods:

• In vitro studies using primary human NSCLC cells and established cell lines (A549, NCI-H1944).
• Assessment of cell growth, proliferation, cell cycle, migration, invasion, and apoptosis.
• Analysis of mTOR complex assembly and key protein phosphorylations (Akt, S6K1, S6).
• In vivo studies using NSCLC xenografts in severe combined immune deficient mice.

Main Results:

• PQR620 inhibited NSCLC cell growth, proliferation, migration, invasion, and induced apoptosis.
• PQR620 disrupted mTOR complexes and blocked Akt, S6K1, and S6 phosphorylation.
• PQR620 demonstrated efficacy via both Akt-mTOR-dependent and -independent pathways, including Sphingosine Kinase 1 (SphK1) inhibition and oxidative stress.
• In vivo, PQR620 potently inhibited NSCLC xenograft growth.

Conclusions:

• PQR620 exhibits significant anti-NSCLC activity through dual mTOR-dependent and -independent mechanisms.
• PQR620's ability to induce apoptosis, inhibit SphK1, and cause oxidative stress contributes to its anti-tumor effects.
• PQR620 shows therapeutic potential for NSCLC treatment.